☰

Shellie M. Callahan, Ph.D. - Publications

Affiliations: 
2005 University of Texas at Austin, Austin, Texas, U.S.A. 
Area:
Molecular Biology
Tree Info Grants Similar researchers PubMed Report error

15 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Jonsson-Schmunk K, Wonganan P, Choi JH, Callahan SM, Croyle MA. Integrin Receptors Play a Key Role in the Regulation of Hepatic Cytochrome P450 3A. Drug Metabolism and Disposition: the Biological Fate of Chemicals. PMID 26868618 DOI: 10.1124/Dmd.115.068874  0.679
2014 Wonganan P, Jonsson-Schmunk K, Callahan SM, Choi JH, Croyle MA. Evaluation of the HC-04 cell line as an in vitro model for mechanistic assessment of changes in hepatic cytochrome P450 3A during adenovirus infection. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 42: 1191-201. PMID 24764148 DOI: 10.1124/Dmd.113.056663  0.681
2008 Callahan SM, Wonganan P, Croyle MA. Molecular and macromolecular alterations of recombinant adenoviral vectors do not resolve changes in hepatic drug metabolism during infection. Virology Journal. 5: 111. PMID 18826641 DOI: 10.1186/1743-422X-5-111  0.756
2008 Callahan SM, Wonganan P, Obenauer-Kutner LJ, Sutjipto S, Dekker JD, Croyle MA. Controlled inactivation of recombinant viruses with vitamin B2. Journal of Virological Methods. 148: 132-45. PMID 18160141 DOI: 10.1016/J.Jviromet.2007.10.027  0.676
2006 Le HT, Boquet MP, Clark EA, Callahan SM, Croyle MA. Renal pathophysiology after systemic administration of recombinant adenovirus: changes in renal cytochromes P450 based on vector dose. Human Gene Therapy. 17: 1095-111. PMID 17069534 DOI: 10.1089/Hum.2006.17.1095  0.726
2006 Callahan SM, Boquet MP, Ming X, Brunner LJ, Croyle MA. Impact of transgene expression on drug metabolism following systemic adenoviral vector administration. The Journal of Gene Medicine. 8: 566-76. PMID 16508909 DOI: 10.1002/Jgm.884  0.748
2005 Callahan SM, Ming X, Lu SK, Brunner LJ, Croyle MA. Considerations for use of recombinant adenoviral vectors: dose effect on hepatic cytochromes P450. The Journal of Pharmacology and Experimental Therapeutics. 312: 492-501. PMID 15496614 DOI: 10.1124/Jpet.104.075374  0.74
2005 Callahan SM, Wonganan P, Obenauer-Kutner LJ, Sutjipto S, Le HT, Croyle MA. 414. Vitamin B2: A Key Component for Controlled Inactivation of Viruses Suitable for Biological Use Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.06.417  0.704
2005 Boquet MP, Le HT, Clark EA, Callahan SM, Croyle MA. 412. Renal Pathophysiology after Systemic Administration of a Recombinant Adenovirus: Changes in Drug Metabolism Based upon Vector Dose Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.06.415  0.744
2005 Le HT, Boquet MP, Clark EA, Callahan SM, Croyle MA. 148. The Transgene Cassette Is Not Fully Responsible for Alterations of Renal Cytochrome P450 Expression after Systemic Administration of Recombinant Adenovirus Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.06.152  0.726
2005 Callahan SM, Boquet MP, Wonganan P, Croyle MA. 142. Molecular and Macromolecular Alterations of Recombinant Adenoviral Vectors Do Not Eliminate Changes in Hepatic Drug Metabolism Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.06.147  0.754
2004 Lu SK, Callahan SM, Jin R, Brunner LJ. Cyclosporine and bromocriptine-induced suppressions of CYP3A1/2 and CYP2C11 are not mediated by prolactin. European Journal of Pharmacology. 501: 215-24. PMID 15464081 DOI: 10.1016/J.Ejphar.2004.08.019  0.538
2004 Croyle MA, Callahan SM, Auricchio A, Schumer G, Linse KD, Wilson JM, Brunner LJ, Kobinger GP. PEGylation of a vesicular stomatitis virus G pseudotyped lentivirus vector prevents inactivation in serum. Journal of Virology. 78: 912-21. PMID 14694122 DOI: 10.1128/Jvi.78.2.912-921.2004  0.688
2003 Liu J, Callahan SM, Brunner LJ. Effect of sodium alterations on hepatic cytochrome P450 3A2 and 2C11 and renal function in rats. Drug Development and Industrial Pharmacy. 29: 767-75. PMID 12906334 DOI: 10.1081/Ddc-120021776  0.421
2003 Lu SK, Callahan SM, Brunner LJ. Suppression of hepatic CYP3A1/2 and CYP2C11 by cyclosporine is not mediated by altering growth hormone levels. The Journal of Pharmacology and Experimental Therapeutics. 305: 331-7. PMID 12649386 DOI: 10.1124/Jpet.102.044776  0.508
Show low-probability matches.